Zevra Therapeutics, Inc. (ZVRA)

Zevra Therapeutics, Inc. (ZVRA) Healthcare & Pipeline Overview

Zevra Therapeutics, Inc. is a U.S.-based rare disease biotechnology company focused on developing proprietary prodrugs using its Ligand Activated Therapy technology. It targets high-need areas like ADHD, stimulant use disorder, and CNS rare diseases, with two FDA-approved products and a pipeline of candidates advancing through clinical trials.

What Is the Investment Thesis for ZVRA?

Zevra Therapeutics, Inc. presents a focused investment profile centered on its proprietary Ligand Activated Therapy technology and a strategic emphasis on rare diseases and high-need CNS disorders. The company's ability to develop improved prodrug versions of existing FDA-approved drugs, alongside novel compounds for new indications, forms a robust foundation for future growth. With two FDA-approved products, AZSTARYS for ADHD and APADAZ for pain, Zevra has established commercial revenue streams. The P/E ratio of 5.9 and a profit margin of 101.6% indicate strong current profitability relative to its market capitalization of $820.52M, suggesting efficient operations and potential for value. Key growth catalysts include the progression of its Phase II pipeline candidates, KP1077 for idiopathic hypersomnia and narcolepsy, and KP879 for stimulant use disorder. Successful clinical trial outcomes and subsequent regulatory approvals for these candidates could significantly expand Zevra's market reach and revenue potential in areas with substantial unmet medical needs. The company's gross margin of 85.5% further underscores its operational efficiency in bringing products to market. The rare disease focus offers potential for market exclusivity and premium pricing, while strategic collaborations enhance development capabilities and market access.

Based on FMP financials and quantitative analysis

ZVRA Key Highlights

• Market Capitalization: $0.65 billion, reflecting its valuation within the biotechnology sector.
• Price-to-Earnings (P/E) Ratio: 6.35, indicating a potentially attractive valuation relative to its earnings.
• Profit Margin: 101.6%, demonstrating exceptional profitability from its operational activities.
• Gross Margin: 85.5%, highlighting strong cost management in its product development and sales processes.
• Beta: 0.88, suggesting lower volatility compared to the broader market, which may appeal to risk-averse investors.

Who Are ZVRA's Competitors?

ZVRA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ZVRA's Key Strengths?

• Proprietary Ligand Activated Therapy technology for prodrug development.
• Two FDA-approved products: AZSTARYS for ADHD and APADAZ for pain.
• Pipeline addressing high-need CNS and rare diseases (KP1077 for IH/narcolepsy, KP879 for stimulant use disorder).
• Established collaboration and license agreements with KVK-Tech, Inc. and Commave Therapeutics SA.

What Are ZVRA's Weaknesses?

• Relatively small employee base (59 employees) for a company with multiple pipeline assets and approved products.
• Significant reliance on the successful outcomes of ongoing and future clinical trials for pipeline candidates.
• Potential for high research and development costs associated with drug discovery and clinical development.
• Limited geographic reach, primarily focused on the United States market.

What Could Drive ZVRA Stock Higher?

• Completion and readout of Phase II clinical trial results for KP1077 for idiopathic hypersomnia and narcolepsy, which could significantly de-risk the asset and inform future development decisions.
• Advancement of KP879 through its Phase II clinical trial for stimulant use disorder, with potential for data readouts that could validate its therapeutic potential and guide subsequent phases.
• Potential initiation of Phase III clinical trials for either KP1077 or KP879, marking a critical milestone towards regulatory submission and commercialization.
• Continued commercialization efforts and market penetration for FDA-approved AZSTARYS in the attention deficit hyperactivity disorder market, driving revenue growth.

What Are the Key Risks for ZVRA?

• Clinical trial failures or delays for pipeline candidates KP1077 and KP879, which could significantly impact future revenue streams, delay market entry, and negatively affect company valuation.
• Regulatory challenges, including non-approval or delays in the approval process for new drug applications, particularly given the stringent requirements for CNS and rare disease treatments.
• Intense competition from established pharmaceutical companies and other biotechnology firms developing treatments for ADHD, stimulant use disorder, narcolepsy, and pain management, potentially limiting market share.
• Intellectual property disputes or challenges to patent validity, which could erode market exclusivity and profitability for approved or pipeline products.
• Market adoption risks for approved products like AZSTARYS and APADAZ, dependent on physician prescribing patterns, payer coverage decisions, and patient acceptance, which can vary widely.

What Are the Growth Opportunities for ZVRA?

• Growth opportunity 1: The successful advancement and potential approval of KP1077 for idiopathic hypersomnia (IH) and narcolepsy represents a significant growth driver. KP1077, currently in Phase II clinical trials, is a prodrug of d-methylphenidate designed to address these chronic neurological conditions. The market for IH and narcolepsy treatments is characterized by a need for improved therapies with better tolerability and efficacy profiles. Successful clinical outcomes and subsequent regulatory approval could unlock access to a specialized market segment, offering a novel treatment option and substantial revenue potential for Zevra Therapeutics within the next 3-5 years, contingent on trial progression and regulatory timelines.
• Growth opportunity 2: The development of KP879 for stimulant use disorder (SUD) offers another substantial growth pathway. This prodrug product candidate is also in Phase II clinical trials, targeting a condition with a significant unmet medical need and limited approved pharmacological treatments. The societal and economic burden of SUD is immense, underscoring the demand for effective therapeutic interventions. If KP879 demonstrates favorable efficacy and safety profiles through clinical development, its potential approval could position Zevra as a key player in addressing this critical public health challenge, opening a large and underserved market within the next 5-7 years, subject to clinical and regulatory success.
• Growth opportunity 3: Expanding market penetration and commercial success of AZSTARYS, Zevra's FDA-approved once-daily treatment for attention deficit hyperactivity disorder (ADHD) in patients aged six years and older. The ADHD market is substantial and continues to grow, driven by increasing diagnoses and demand for effective, convenient treatments. Zevra can capitalize on this by implementing robust marketing and sales strategies, securing favorable formulary placements, and demonstrating the differentiated benefits of AZSTARYS. Continued growth in prescriptions and market share for AZSTARYS represents an ongoing and immediate revenue enhancement opportunity for the company.
• Growth opportunity 4: Leveraging the proprietary Ligand Activated Therapy technology platform to discover and develop new prodrug candidates for additional serious medical conditions. Zevra's core technology is a versatile asset that can be applied to a broader range of existing compounds or new chemical entities to create prodrugs with enhanced therapeutic properties. This strategic approach allows for the continuous replenishment and expansion of its pipeline beyond current lead candidates, tapping into new disease indications and market opportunities. This platform offers long-term growth potential by diversifying Zevra's product portfolio and reducing reliance on a few key assets, with new pipeline candidates potentially emerging within a 3-7 year timeframe.
• Growth opportunity 5: Pursuing new strategic collaborations and licensing agreements with pharmaceutical partners. Zevra's existing collaborations with KVK-Tech, Inc. and Commave Therapeutics SA demonstrate its capability to forge partnerships. Expanding these alliances, either for co-development of pipeline assets, out-licensing specific compounds for broader market reach (e.g., international markets), or in-licensing complementary technologies, could accelerate development timelines, share R&D costs, and broaden commercialization capabilities. Such partnerships can provide non-dilutive funding and access to larger sales forces, enhancing Zevra's ability to compete and grow within the global pharmaceutical market over the next 1-5 years.

What Opportunities Does ZVRA Have?

• Successful advancement and regulatory approval of KP1077 and KP879, opening new significant market segments.
• Expansion of approved products into new indications or patient populations.
• Leveraging the Ligand Activated Therapy platform to develop additional prodrug candidates for other unmet medical needs.
• Forging new strategic partnerships for co-development, commercialization, or international market expansion.

What Threats Does ZVRA Face?

• Clinical trial failures or delays for KP1077 and KP879, impacting future revenue streams and valuation.
• Intense competition from established pharmaceutical companies and other biotechnology firms in targeted therapeutic areas.
• Regulatory hurdles, including potential non-approval or delays in the approval process for new drug applications.
• Intellectual property challenges or patent expirations affecting market exclusivity for its products.
• Market adoption challenges for new drugs, dependent on physician prescribing patterns, payer coverage, and patient acceptance.

What Are ZVRA's Competitive Advantages?

• Proprietary Ligand Activated Therapy technology, which provides a unique platform for developing prodrugs with potentially improved profiles.
• FDA approvals for AZSTARYS and APADAZ, representing significant regulatory achievements and market entry barriers for competitors.
• Focus on rare diseases and high-need CNS disorders, which often benefit from orphan drug designations and reduced competition.
• Intellectual property surrounding its specific prodrug compounds and the Ligand Activated Therapy platform.
• Strategic collaboration and license agreements with partners like KVK-Tech, Inc. and Commave Therapeutics SA, enhancing development and commercialization capabilities.

What Does ZVRA Do?

Zevra Therapeutics, Inc., incorporated in 2006 and formerly known as KemPharm, Inc. until its name change in February 2023, is a U.S.-based rare disease company headquartered in Celebration, Florida. The company is dedicated to melding science to discover and develop various proprietary prodrugs aimed at treating serious medical conditions. Central to its strategy is the Ligand Activated Therapy technology, which enables Zevra to generate improved prodrug versions of existing FDA-approved drugs. This technology also facilitates the creation of prodrug versions of compounds that may have novel applications for new disease indications, thereby expanding therapeutic possibilities. Zevra's product candidate pipeline is strategically focused on high-need areas within central nervous system (CNS) disorders, including attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and CNS rare diseases such as idiopathic hypersomnia (IH). The company's lead product candidate, KP1077, is currently undergoing Phase II clinical trials for the treatment of both IH and narcolepsy. This candidate is based on a prodrug of d-methylphenidate, known as serdexmethylphenidate. Additionally, Zevra is advancing KP879, another prodrug product candidate, which is also in Phase II clinical trials for the treatment of stimulant use disorder. Beyond its pipeline, Zevra Therapeutics has successfully secured FDA approval for two significant products: AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older, and APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen for pain management. The company's product pipeline also includes arimoclomol. Zevra Therapeutics further strengthens its operational capabilities through collaboration and license agreements with strategic partners such as KVK-Tech, Inc. and Commave Therapeutics SA, leveraging external expertise and resources to advance its mission of addressing unmet medical needs.

What Products and Services Does ZVRA Offer?

• Discovers and develops proprietary prodrugs to treat serious medical conditions in the United States.
• Utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs.
• Generates prodrug versions of existing compounds that may have applications for new disease indications.
• Focuses its prodrug product candidate pipeline on attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases, including idiopathic hypersomnia (IH).
• Has a lead product candidate, KP1077, in Phase II clinical trial for the treatment of IH and narcolepsy.
• Is developing KP879, a prodrug product candidate, in Phase II clinical trial for the treatment of stimulant use disorder.
• Received FDA approval for AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients age six years and older.
• Received FDA approval for APADAZ, an immediate-release combination product containing benzhydrocodone and acetaminophen for pain.

How Does ZVRA Make Money?

• Generates revenue from the commercial sales of its FDA-approved products, AZSTARYS for ADHD and APADAZ for pain management.
• Potentially receives milestone payments and royalties through collaboration and license agreements, such as those with KVK-Tech, Inc. and Commave Therapeutics SA.
• Invests significantly in research and development to advance its proprietary prodrug candidates through preclinical and clinical trial phases.
• Aims to secure additional regulatory approvals for its pipeline products to expand its market presence and create new revenue streams.
• Leverages its Ligand Activated Therapy technology to create intellectual property, which underpins its product development and commercialization efforts.

What Industry Does ZVRA Operate In?

Zevra Therapeutics operates within the highly specialized and competitive biotechnology industry, specifically targeting the rare disease and central nervous system (CNS) therapeutic areas. The biotechnology sector is characterized by extensive research and development cycles, significant capital investment, and stringent regulatory pathways. The rare disease market, while smaller in patient population, often benefits from expedited regulatory reviews, longer market exclusivity periods, and premium pricing due due to high unmet medical needs. Zevra's focus on prodrug technology positions it to potentially offer improved safety profiles, enhanced efficacy, or more convenient dosing regimens compared to existing treatments. The competitive landscape includes both large pharmaceutical companies with established CNS portfolios and smaller biotech firms developing novel therapies. Zevra differentiates itself through its proprietary Ligand Activated Therapy platform, aiming to carve out market share by addressing specific patient populations with tailored, improved drug formulations in high-need areas like ADHD, stimulant use disorder, idiopathic hypersomnia, and narcolepsy.

Who Are ZVRA's Key Customers?

• Patients aged six years and older diagnosed with Attention Deficit Hyperactivity Disorder (ADHD) who are prescribed AZSTARYS.
• Individuals suffering from stimulant use disorder, for whom KP879 is being developed as a potential treatment.
• Patients diagnosed with idiopathic hypersomnia (IH) and narcolepsy, targeted by the lead product candidate KP1077.
• Patients requiring immediate-release combination products for pain management, for whom APADAZ is approved.
• Healthcare providers, including physicians, psychiatrists, and neurologists, who prescribe Zevra's medications to their patients.

Net buyingInsider Activity

Over the past six months, Zevra Therapeutics, Inc. insiders filed 29 SEC Form 4 transactions — 12 sales and 17 purchases. On net that is roughly 617K shares acquired (about $5.7M) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Zevra Therapeutics, Inc.

Revenue for Zevra Therapeutics, Inc. came in at $36.2M during Q1 2026, a 6.1% improvement versus the preceding quarter. The company recorded net income of $37.9M, with diluted EPS of $0.63. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this small-cap Healthcare company. Across the four most recent quarters, ZVRA averaged $0.54 in diluted EPS.

ZVRA Valuation & Market Position

With a $820.52M market cap, Zevra Therapeutics, Inc. sits in the small-cap segment of the market. Relative to its peer group, ZVRA's quantitative score of 77/100 is roughly in line with the peer average of 77/100.

ROE 81%Key Financial Metrics

Return on equity for Zevra Therapeutics, Inc. stands at 81.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 44.6%, showing how much profit it generates from its asset base. ZVRA trades at a trailing price-to-earnings ratio of 5.92, below the Healthcare sector average of ~23x. Its free cash flow yield is 1.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.89 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 15.4%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 7/9Financial Health

Zevra Therapeutics, Inc.'s Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 7.74 places it in the safe zone, indicating low near-term bankruptcy risk.

4/8 beatsEarnings Track Record

Zevra Therapeutics, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 293.4% above estimates on average.

FY2026 estForward Outlook

Wall Street analysts project Zevra Therapeutics, Inc. revenue of about $145.7M for fiscal 2026, with EPS near $1.07. The estimate reflects 7 contributing analysts.

Company Profile

Zevra Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Celebration, US. The company is led by CEO Neil F. McFarlane. ZVRA has traded publicly since 2015.

ZVRA Financials

ZVRA Latest News

ZVRA Analyst Consensus

ZVRA MoonshotScore

What Investors Ask About Zevra Therapeutics, Inc. (ZVRA) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources